Drug Profile


Alternative Names: F-351

Latest Information Update: 29 Aug 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Shanghai Genomics
  • Class Antifibrotics; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Collagen inhibitors; Fibroblast growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatic fibrosis
  • Preclinical Renal failure
  • Discontinued Pulmonary fibrosis

Most Recent Events

  • 11 Mar 2016 Preclinical trials in Hepatic fibrosis in USA (PO) before March 2016
  • 11 Mar 2016 GNI files an IND application with the FDA in USA for Hepatic fibrosis (GNI Presentation, March 2016)
  • 01 Jul 2015 Phase-II clinical trials in Hepatic fibrosis in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top